With global attention fixated on the race to get the COVID-19 vaccine into as many arms as possible, new developments are generating headlines about Emergent BioSolutions, and its Baltimore vaccine manufacturing center.
The Gaithersburg-based company signed on last year to make the Johnson & Johnson vaccine, but the effort is now being overseen by the J&J following a mix-up that ruined 15 million doses.
Emergent may be new to the spotlight when it comes to world headlines, but it has been around. The company was founded in 1998 and went public in 2006. In Baltimore, its presence has been expanding as part of a mix of biotech companies growing a footprint in close proximity to government and medical institutions in Maryland. Long viewed among the vanguard of a local biotech industry that is increasingly making treatments as well as developing new ones in the lab, it is now the source of delays to vaccination in a global pandemic.
READ FULL ARTICLE HERE
